Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma

Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
ShareXFacebook

(MedPage Today) -- The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma. A next-generation...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Competition Builds for Novel IgA Nephropathy Approach
MedPage Today

Competition Builds for Novel IgA Nephropathy Approach

(MedPage Today) -- Patients with immunoglobulin A (IgA) nephropathy had less protein in their urine -- a key surrogate marker for the renal impairment caused by the condition -- after treatment with a dual-acting biologic agent that inhibits...

Read more →
Advertisement